BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25450647)

  • 1. Relationship between NOB1 expression and prognosis of resected non-small cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Biol Markers; 2015 Feb; 30(1):e43-8. PubMed ID: 25450647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer.
    Pøhl M; Olsen KE; Holst R; Donnem T; Busund LT; Bremnes RM; Al-Saad S; Andersen S; Richardsen E; Ditzel HJ; Hansen O
    Acta Oncol; 2016; 55(2):167-77. PubMed ID: 26057535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
    J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
    Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
    Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
    Traynor AM; Weigel TL; Oettel KR; Yang DT; Zhang C; Kim K; Salgia R; Iida M; Brand TM; Hoang T; Campbell TC; Hernan HR; Wheeler DL
    Lung Cancer; 2013 Jul; 81(1):138-41. PubMed ID: 23628526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-level expression of Hsp90β is associated with poor survival in resectable non-small-cell lung cancer patients.
    Kim SH; Ji JH; Park KT; Lee JH; Kang KW; Park JH; Hwang SW; Lee EH; Cho YJ; Jeong YY; Kim HC; Lee JD; Jang I; Lee JS; Lee HW; Lee GW
    Histopathology; 2015 Oct; 67(4):509-19. PubMed ID: 25704653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
    Cui D; Yu CH; Liu M; Xia QQ; Zhang YF; Jiang WL
    Tumour Biol; 2016 Mar; 37(3):4127-34. PubMed ID: 26490983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOB1 in non-small-cell lung cancer: expression profile and clinical significance.
    Liu K; Gu MM; Chen HL; You QS
    Pathol Oncol Res; 2014 Apr; 20(2):461-6. PubMed ID: 24272676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs.
    Xu JY; Lu S; Xu XY; Hu SL; Li B; Li WX; Chang JY
    Tumour Biol; 2016 Aug; 37(8):10349-56. PubMed ID: 26846099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo.
    Li Y; Ma C; Qian M; Wen Z; Jing H; Qian D
    Oncol Rep; 2014 Mar; 31(3):1271-6. PubMed ID: 24452698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer.
    Li J; Zhang JT; Jiang X; Shi X; Shen J; Feng F; Chen J; Liu G; He P; Jiang J; Tsang LL; Wang Y; Rosell R; Jiang L; He J; Chan HC
    Int J Oncol; 2015 May; 46(5):2107-15. PubMed ID: 25760446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.